Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany

The aim of the study was to update previously published public health impact and cost-effectiveness analyses of the recombinant zoster vaccine (RZV), in the German population aged ≥50 years of age (YOA), with the latest vaccine efficacy (VE) estimates against herpes zoster (HZ). The updated estimate...

Full description

Bibliographic Details
Main Authors: Desmond Curran, Desirée Van Oorschot, Sean Matthews, Johannes Hain, Ahmed Ehab Salem, Magdalena Schwarz
Format: Article
Language:English
Published: Taylor & Francis Group 2021-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
public health impact
cost effectiveness
vaccination
number needed to vaccinate
Online Access:http://dx.doi.org/10.1080/21645515.2021.2002085

Internet

http://dx.doi.org/10.1080/21645515.2021.2002085

Similar Items